PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Department of Gastroenterology, Royal Devon and Exeter NHS Foundation Trust, Exeter, UK.\', \'Exeter Inflammatory Bowel Disease and Pharmacogenetics Research Group, University of Exeter, Exeter, UK.\', \'Department of Gastroenterology, St Marks Hospital and Academic Institute, London, UK.\', \'Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK.\', \'Department of Infectious Disease, Imperial College London, London, UK.\', \'Department of Immunology and Inflammation, Imperial College London, London, United Kingdom.\', \'Department of Biochemistry, Exeter Clinical Laboratory International, Royal Devon and Exeter NHS Foundation Trust, Exeter, UK.\', \'IBD Unit, Department of Gastroenterology, Hull University Teaching Hospitals NHS Trust, Hull, UK.\', \'Hull York Medical School, University of Hull, Hull, UK.\', \'Department of Gastroenterology, Imperial College Healthcare NHS Trust, London, UK.\', \'Department of Gastroenterology, Royal Free London NHS Foundation Trust, London, UK.\', \'Genetic Mechanisms of Disease Laboratory, The Francis Crick Institute, London, UK.\', \'Cambridge Institute of Therapeutic Immunology and Infectious Disease, Jeffrey Cheah Biomedical Centre, Cambridge Biomedical Campus, University of Cambridge, Cambridge, UK.\', \'Department of Gastroenterology, Guy\'s and St Thomas\' NHS Foundation Trust, London, UK.\', \'School of Immunology & Microbial Sciences, King\'s College London, London, UK.\', \'Department of Gastroenterology, Western General Hospital, NHS Lothian, Edinburgh, UK.\', \'Centre for Inflammation Research, The Queen\'s Medical Research Institute, The University of Edinburgh, Edinburgh, UK.\', \'Department of Gastroenterology, Royal London Hospital, Barts Health NHS Trust, London, UK.\', \'Centre for Immunobiology, Blizard Institute, Barts and the London School of Medicine, Queen Mary University of London, London, UK.\', \'Department of Gastroenterology, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.\', \'Translational & Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.\', \'Institute of Genetic and Molecular Medicine, University of Edinburgh, Edinburgh, UK.\', \'Lung Division, Royal Brompton Hospital and Harefield Hospitals, London, UK.\', \'Department of Gastroenterology, Royal Devon and Exeter NHS Foundation Trust, Exeter, UK. tariq.ahmad1@nhs.net.\', \'Exeter Inflammatory Bowel Disease and Pharmacogenetics Research Group, University of Exeter, Exeter, UK. tariq.ahmad1@nhs.net.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • 10.1038/s41467-022-28517-z
?:hasPublicationType
?:journal
  • Nature communications
is ?:pmid of
?:pmid
?:pmid
  • 35296643
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 6.582
?:rankingScore_hIndex
  • 198
is ?:relation_isRelatedTo_publication of
?:title
  • Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab.
?:type
?:year
  • 2022

Metadata

Anon_0  
expand all